Nuvation Bio Inc. (NYSE:NUVB) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts give Nuvation Bio a consensus rating of Moderate Buy from 10 brokerages (8 buys, 1 hold, 1 sell) with an average 1‑year target price of $11.63.
• Shares trade around $4.48 with a market cap of $1.56B and a 52‑week range of $1.57–$9.75; the company reported quarterly EPS of ($0.11) (in line) and revenue of $41.9M (beat estimates) but remains unprofitable with analysts forecasting -$0.36 EPS for the year.
• Institutional ownership is high at 61.67%, highlighted by significant fourth‑quarter activity including Invesco boosting its stake 138.2% to 1,185,143 shares and new positions from Corient, NewEdge and Voloridge.

Shares of Nuvation Bio Inc. (NYSE:NUVB - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten brokerages that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $11.6250.

Several equities analysts recently issued reports on the stock. HC Wainwright dropped their target price on shares of Nuvation Bio from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Monday, January 12th. UBS Group dropped their target price on shares of Nuvation Bio from $10.00 to $7.00 and set a "neutral" rating on the stock in a report on Tuesday, March 3rd. Wedbush restated an "outperform" rating and issued a $11.00 target price on shares of Nuvation Bio in a report on Thursday, April 2nd. Weiss Ratings restated a "sell (d-)" rating on shares of Nuvation Bio in a report on Thursday, January 22nd. Finally, Truist Financial set a $13.00 target price on shares of Nuvation Bio in a report on Tuesday, January 27th.

Hedge Funds Weigh In On Nuvation Bio

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC acquired a new position in Nuvation Bio in the fourth quarter valued at $2,277,000. Invesco Ltd. increased its stake in Nuvation Bio by 138.2% in the fourth quarter. Invesco Ltd. now owns 1,185,143 shares of the company's stock valued at $10,619,000 after purchasing an additional 687,597 shares in the last quarter. Beacon Pointe Advisors LLC increased its stake in Nuvation Bio by 60.4% in the fourth quarter. Beacon Pointe Advisors LLC now owns 259,212 shares of the company's stock valued at $2,323,000 after purchasing an additional 97,612 shares in the last quarter. NewEdge Advisors LLC bought a new stake in Nuvation Bio in the fourth quarter valued at $8,531,000. Finally, Voloridge Investment Management LLC bought a new stake in Nuvation Bio in the fourth quarter valued at $3,664,000. Institutional investors and hedge funds own 61.67% of the company's stock.

Nuvation Bio Price Performance

Shares of NYSE:NUVB opened at $4.48 on Wednesday. The firm has a market cap of $1.56 billion, a PE ratio of -7.47 and a beta of 1.60. The firm's fifty day moving average is $5.02 and its 200-day moving average is $5.77. The company has a debt-to-equity ratio of 0.15, a quick ratio of 6.81 and a current ratio of 6.95. Nuvation Bio has a 52 week low of $1.57 and a 52 week high of $9.75.

Nuvation Bio (NYSE:NUVB - Get Free Report) last released its earnings results on Monday, March 2nd. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.11). The business had revenue of $41.87 million for the quarter, compared to analyst estimates of $36.82 million. Nuvation Bio had a negative net margin of 325.31% and a negative return on equity of 57.48%. Sell-side analysts predict that Nuvation Bio will post -0.36 earnings per share for the current year.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company's pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.